Literature DB >> 10913479

Management of sexual dysfunction in patients with cardiovascular disease: recommendations of The Princeton Consensus Panel.

R DeBusk, Y Drory, I Goldstein, G Jackson, S Kaul, S E Kimmel, J B Kostis, R A Kloner, M Lakin, C M Meston, M Mittleman, J E Muller, H Padma-Nathan, R C Rosen, R A Stein, R Zusman.   

Abstract

Sexual dysfunction is highly prevalent in both sexes and adversely affects patients' quality of life and well being. Given the frequent association between sexual dysfunction and cardiovascular disease, in addition to the potential cardiac risk of sexual activity itself, a consensus panel was convened to develop recommendations for clinical management of sexual dysfunction in patients with cardiovascular disease. Based upon a review of the research and presentations by invited experts, a classification system was developed for stratification of patients into high, low, and intermediate categories of cardiac risk. The large majority of patients are in the low-risk category, which includes patients with (1) controlled hypertension; (2) mild, stable angina; (3) successful coronary revascularization; (4) a history of uncomplicated myocardial infarction (MI); (5) mild valvular disease; and (6) no symptoms and <3 cardiovascular risk factors. These patients can be safely encouraged to initiate or resume sexual activity or to receive treatment for sexual dysfunction. An important exception is the use of sildenafil in patients taking nitrates in any form. Patients in the intermediate-risk category include those with (1) moderate angina; (2) a recent MI (<6 weeks); (3) left ventricular dysfunction and/or class II congestive heart failure; (4) nonsustained low-risk arrhythmias; and (5) >/=3 risk factors for coronary artery disease. These patients should receive further cardiologic evaluation before restratification into the low- or high-risk category. Finally, patients in the high-risk category include those with (1) unstable or refractory angina; (2) uncontrolled hypertension; (3) congestive heart failure (class III or IV); (4) very recent MI (<2 weeks); (5) high-risk arrhythmias; (6) obstructive cardiomyopathies; and (7) moderate-to-severe valvular disease. These patients should be stabilized by specific treatment for their cardiac condition before resuming sexual activity or being treated for sexual dysfunction. A simple algorithm is provided for guiding physicians in the management of sexual dysfunction in patients with varying degrees of cardiac risk.

Entities:  

Mesh:

Year:  2000        PMID: 10913479     DOI: 10.1016/s0002-9149(00)00896-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  31 in total

1.  Role of exercise treadmill testing in the management of erectile dysfunction: a joint cardiovascular/erectile dysfunction clinic.

Authors:  H Solomon; J Man; E Martin; G Jackson
Journal:  Heart       Date:  2003-06       Impact factor: 5.994

2.  miR-126-5p regulates H9c2 cell proliferation and apoptosis under hypoxic conditions by targeting IL-17A.

Authors:  Yin Ren; Ruanzhong Bao; Zhujun Guo; Jin Kai; Chen-Ge Cai; Zhu Li
Journal:  Exp Ther Med       Date:  2020-11-23       Impact factor: 2.447

3.  Let's talk about sex.

Authors:  Graham Jackson
Journal:  Clin Res Cardiol       Date:  2013-02-21       Impact factor: 5.460

Review 4.  Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles?

Authors:  Wolfgang Aichhorn; Alexandra B Whitworth; Elisabeth M Weiss; Josef Marksteiner
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 5.  Cardiovascular safety of sildenafil.

Authors:  Diane Tran; Laurence Guy Howes
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 6.  The use of phosphodiesterase 5 inhibitors with concomitant medications.

Authors:  G Corona; E Razzoli; G Forti; M Maggi
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

7.  Sildenafil citrate does not alter ventricular repolarization properties: novel evidence from dynamic QT analysis.

Authors:  Dayimi Kaya; Cem Guler; Ali Metin Esen; Irfan Barutcu; Cetin Dincel
Journal:  Ann Noninvasive Electrocardiol       Date:  2004-07       Impact factor: 1.468

8.  General practitioner views about discussing sexual issues with patients with coronary heart disease: a national survey in Ireland.

Authors:  Molly Byrne; Sally Doherty; Hannah M McGee; Andrew W Murphy
Journal:  BMC Fam Pract       Date:  2010-05-25       Impact factor: 2.497

9.  Patient preference and satisfaction in erectile dysfunction therapy: a comparison of the three phosphodiesterase-5 inhibitors sildenafil, vardenafil and tadalafil.

Authors:  Amr Abdel Raheem; Philip Kell
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

Review 10.  Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction.

Authors:  R Sadovsky; G B Brock; S W Gutkin; S Sorsaburu
Journal:  Int J Clin Pract       Date:  2009-08       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.